These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36349941)

  • 1. Updates in heart failure: sodium glucose co-transporter 2 inhibitors and beyond - major changes are coming.
    Cimino G; Pancaldi E; Tomasoni D; Lombardi CM; Metra M; Adamo M
    J Cardiovasc Med (Hagerstown); 2022 Dec; 23(12):761-769. PubMed ID: 36349941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS; Correa A; Contreras JP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology.
    Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; de Boer RA; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund L; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
    Eur J Heart Fail; 2020 Sep; 22(9):1495-1503. PubMed ID: 32618086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of sodium glucose co-transporter 2 inhibitors in acute heart failure: a practical guidance.
    Ferreira JP; Pimenta J; Moura B; Aguiar C; Franco F
    ESC Heart Fail; 2022 Dec; 9(6):4344-4347. PubMed ID: 36004699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Serendipity of sodium-glucose co-transporter 2 inhibitors: a new paradigm in the management of heart failure with reduced ejection fraction].
    Rosano G; Iacoviello M; Filardi PP
    G Ital Cardiol (Rome); 2021 Apr; 22(4):277-283. PubMed ID: 33783447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
    Tsampasian V; Elghazaly H; Chattopadhyay R; Ali O; Corballis N; Chousou PA; Clark A; Garg P; Vassiliou VS
    Eur J Prev Cardiol; 2022 May; 29(6):e227-e229. PubMed ID: 34850881
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys.
    Lioudaki E; Joslin JR; Trachanatzi E; Androulakis E
    Rev Cardiovasc Med; 2022 Mar; 23(3):82. PubMed ID: 35345249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose co-transporter-2 inhibitors in the non-diabetic heart failure patient.
    Essa H; Walker L; Sankaranarayanan R
    Br J Clin Pharmacol; 2022 Jun; 88(6):2566-2570. PubMed ID: 34622474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future.
    Nana M; Morgan H; Bondugulapati LNR
    Heart Fail Rev; 2021 Jul; 26(4):953-960. PubMed ID: 32020487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials.
    Liang B; Gu N
    Int J Med Sci; 2022; 19(7):1118-1121. PubMed ID: 35919809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promise of sodium-glucose co-transporter-2 inhibitors in heart failure with mildly reduced ejection fraction.
    Shen X; Shen X
    ESC Heart Fail; 2022 Aug; 9(4):2239-2248. PubMed ID: 35642772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
    Lan NSR; Fegan PG; Yeap BB; Dwivedi G
    ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Another brick in the wall of cardioprotection? A meta-analysis addressing the effect of sodium-glucose co-transporter 2 inhibitors on left ventricular mass assessed by cardiovascular magnetic resonance in patients with heart failure with reduced ejection fraction.
    Patoulias D; Boulmpou A; Doumas M; Papadopoulos CE
    J Cardiovasc Med (Hagerstown); 2022 Aug; 23(8):570-572. PubMed ID: 35905005
    [No Abstract]   [Full Text] [Related]  

  • 14. Sodium-glucose co-transporter-2 inhibitors in heart failure with reduced ejection fraction: Current evidence and future perspectives.
    Jensen J; Omar M; Kistorp C; Gustafsson F; Køber L; Møller JE; Schou M
    Basic Clin Pharmacol Toxicol; 2022 Jul; 131(1):5-17. PubMed ID: 35510595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of heart failure with sodium glucose co-transporter-2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions.
    Sharma A; Butler J; Zieroth S; Giannetti N; Verma S
    Diabet Med; 2019 Dec; 36(12):1550-1561. PubMed ID: 31536660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology Focus: Clinical Evidence for the Use of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction.
    Berendse J; Newenhouse L
    S D Med; 2022 Jul; 75(7):328-329. PubMed ID: 36542574
    [No Abstract]   [Full Text] [Related]  

  • 17. Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure.
    Liang B; Gu N
    Cardiovasc Diabetol; 2022 May; 21(1):84. PubMed ID: 35624512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.
    Tamaki S; Yamada T; Watanabe T; Morita T; Furukawa Y; Kawasaki M; Kikuchi A; Kawai T; Seo M; Abe M; Nakamura J; Yamamoto K; Kayama K; Kawahira M; Tanabe K; Fujikawa K; Hata M; Fujita Y; Umayahara Y; Taniuchi S; Sanada S; Shintani A; Fukunami M
    Circ Heart Fail; 2021 Mar; 14(3):e007048. PubMed ID: 33663235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial'.
    Kokhan E; Kiyakbaev G; Medovchshikov V
    Eur J Heart Fail; 2022 Jul; 24(7):1323-1324. PubMed ID: 35238461
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.